RBC Capital Defends XenoPort (XNPT); Analyst Notes M&A Potential
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to RBC Capital Defends XenoPort (XNPT); Analyst Notes M&A Potential
September 15, 2015 11:10 AM EDT
Cowen analyst Eric Schmidt reiterated an Market Perform rating on XenoPort (NASDAQ: XNPT) noting the XP23829 was active in the latest data but "unimpressive."
Schmidt commented, "XenoPort released Phase II data on '829 (a prodrug of monomethyl fumarate) for the treatment of moderate... More
September 15, 2015 8:03 AM EDT
RBC Capital maintained an Outperform rating on XenoPort (NASDAQ: XNPT) with a price target of $10. Earlier XenoPort announced positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. Analyst Michael J. Yee... More
September 15, 2015 6:34 AM EDT
XenoPort (NASDAQ: XNPT) announced positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. XP23829 met its primary endpoint in both 800 mg once daily and 400 mg twice daily doses, demonstrating statistically significant improvements in percent change from baseline to week 12 in Psoriasis Area and Severity Index (PASI) score. XP23829 is a patented prodrug of monomethyl fumarate (MMF) in a novel oral formulation that was designed to potentially offer physicians and patients an effective, better tolerated and easier to use therapeutic option to currently... More
